Colorectal Cancer Diagnosis by detection of MicroRNA-92 in the Serum
Colorectal cancer is the third most prevalent tumor worldwide, with a median age of 53 years and a predominance in men. We desperately require a gold standard for early detection and non-invasive diagnosis. Micro RNA 92a, a novel tumor marker, was shown to be highly concentrated in the serum of colorectal cancer patients. The present study aimed to assess the miR-92a expression level as a stable blood-based biomarker for the detection of colorectal cancer. This prospective observational study was carried out on 65 subjects. The cases group comprised 44 consecutive naive patients with colorectal cancer proved by colonoscopy and histopathological examination of biopsied specimens. Twenty-one subjects without colorectal cancer and normal colonoscopy served as the control group. Quantitative real-time RT-PCR was applied to determine the relative expression level of miRNA-92a in serum. According to the findings of the histopathological examination of surgically removed specimens, the final stage of colorectal cancer patients was determined. Serum miR-92a expression was significantly higher in the cases group compared to the control. Serum miR-92a levels revealed a significant positive correlation with both TNM (P=0.008) and MAColler stages (P=0.014), as well as a highly significant positive correlation with the tumor size (P=0.001). A statistically significant positive correlation was found between age (p= 0.005) and no significant Correlation between serum miR-92a level with sex and Duke's stage. Serum levels of miR-92a were significantly higher in the cases group. Serum levels of miR-92a showed a significant positive correlation with both TNM and MAColler stages.